The limited availability of Wegovy injections could potentially lead to decreased sales for Novo Nordisk in the short term, affecting the company's financial performance and possibly its stock price. The uncertainty regarding the duration of the shortage adds to the potential negative impact, as it could deter healthcare providers and patients from relying on Wegovy, opting for alternative treatments instead.